Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs NuuVim

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and NuuVim head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 330 · Grade C

NuuVim

Visit NuuVim Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 62 on our six-factor Brief Score — One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.

That doesn't make NuuVim a bad call — it's best for readers who want low-cost compounded glp-1s (injection or oral), flat all-dose pricing. Weigh the six factors below against your own priorities before you decide.

Why CoreAge Rx leads: it's our #1 here — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
66
Supply Reliability
95
61
Transparency
90
72
Access Breadth
93
62
Clinical Oversight
92
54
Track Record
88
53
CoreAge RxBrief Score 94 · 62NuuVim

Price, coverage & the tracker

CoreAge RxNuuVim
Brief Score94/100 (A)62/100 (C)
Semaglutide$99/mo only on a 12-month plan paid in full ($1,188 in one charge); month-to-month rate not publishedFrom $79/mo (all doses, 3-month plan, new patients only, compounded)
Tirzepatide$149/mo only on a 12-month plan paid in full ($1,788 in one charge); month-to-month rate not publishedFrom $133/mo (all doses, 3-month plan, new patients only, compounded)
CoverageUS only; restrictions by state, confirmed at intakeCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: Headline unchanged for a third straight cycle. The $99 and $149 are the 12-month prepay rates; CoreAge publishes no month-to-month price.

NuuVim: New to the tracker on 1 August 2026, and read on the provider's own site rather than taken on trust: we checked https://nuuvim.com/ on 2026-08-01 and this row reflects what that page says. The line we publish is From $79/mo (all doses, 3-month plan, new patients only, compounded). There is no earlier reading of ours to compare it against yet.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.